Top View
- Use of Combinations Comprising a Corticosteroid and a Pyrimidopyrimidine in the Treatment of Inflammatory Diseases
- Combined Deep Learning and Molecular Docking Simulations to Identify Most Promising Candidates from the List of FDA Approved Drugs That Can Be Repurposed to Treat
- Npgrj NCHEMBIO 806 415..416
- Oxatomide(KW・4354)の 薬 理作用(第5報)
- A Review on Fast Dissolving Tablets
- NVA237 / Glycopyrronium Bromide Multinational, Multi-Database Cohort
- Oxatomide Inhibits Interleukin-8 Release from Respiratory Epithelial Cells*
- H1‐Antihistamines for Primary Mast Cell Activation Syndromes (MCAS): a Systematic Review
- The Calculation of Physicochemical Descriptors and Their Application in Predicting Properties of Drugs and Other Compounds
- Management of Drug Overdose and Poisoning
- Use of Antihistamines in Pediatrics a Del Cuvillo,1 J Sastre,2 J Montoro,3 I Jáuregui,4 M Ferrer,5 I Dávila,6 J Bartra,7 J Mullol,8 a Valero,7
- Bioactive Compound Library Plus (96-Well)
- Wo 2007/044693 A2
- Pheniramine Maleate
- Guidance Document on Using in Vitro Data to Estimate in Vivo Starting Doses for Acute Toxicity
- 5-HT Receptor Serotonin Receptor; 5-Hydroxytryptamine Receptor
- Mosser Et Al Figs 190702
- United States Patent (19) (11) Patent Number: 5,250,529 Theoharides 45) Date of Patent: Oct
- Drug Class Review: Newer Antihistamines
- 201373Orig1s000
- Therapeutic and Toxic Blood Concentrations of More Than 1100 Drugs and Other Xenobiotics
- Pruritus in Patients with Amyopathic Dermatomyositis Dimitri Poddighe1* , Zaure Mukusheva2 and Maikesh Assylbekova1,2
- ( 12 ) United States Patent ( 10 ) Patent No.: US 10,675,278 B2 Arkenau -Mari? Et Al
- 0Bcore Safety Profile
- Principali Interazioni Dei Farmaci Onco-Ematologici Con Farmaci, Fitoterapici Ed Alimenti
- Pharmaceutical Appendix to the Tariff Schedule 2
- An Overview of Anti-Allergic Drug Therapy and the Histamine-1 Antihistamines
- Reporting Sodium Channel Activity Using Calcium Flux: Pharmacological Promiscuity of Cardiac Nav1.5
- ICD-10-CM Table of Drugs 2019
- Antihistamines for Allergic Rhinitis Treatment from the Viewpoint of Nonsedative Properties
- Cyp3a Time Dependent Inhibition Risk Assessment
- Therapeutic and Toxic Blood Concentrations of More Than 800 Drugs and Other Xenobiotics
- Classification of Sedating Antihistamines
- Participation of Histamine in the Step-Through Active Avoidance Response and Its Inhibition by H1-Blockers
- Nam Eml 2008.Pdf
- Prediction of Biopharmaceutical Drug Disposition Classification System (BDDCS) by Structural Parameters
- Urticaria Caused by Antihistamines
- Serotoninergic Receptors in Brain Tissue" Properties and Identification of Various Ah-Ligand Binding Sites in Vitro
- Pharmaceutical Fee Schedule